Consumption of sesame seeds and sesame products has favorable effects on blood glucose levels but not on insulin resistance: A systematic review and meta‐analysis of controlled clinical trials

<jats:title>Abstract</jats:title><jats:p>Sesame, with an oily seed containing oil, lignans, and proteins, is a popular plant that has demonstrated health benefits such as antioxidative, antiobesity, and antiinflammatory effects. In this systematic review and meta‐analysis, we aimed to summarize the effect of sesame seeds and their consumption compared to a control group on blood glucose and insulin resistance in human adults. PubMed/MEDLINE, SCOPUS, Web of Science, Google Scholar, and EMBASE were searched to identify eligible controlled clinical trials up to February 2021. Finally, eight clinical trials were included in this study. Sesame products used in these trials were sesame oil, sesamin, and tahini, and the duration of the intervention varied from 45 days to 9 weeks. Our results showed the significant positive effects of sesame and its products on fasting blood glucose FBG (weighted mean difference, WMD: −21.31 mg/dl, 95% CI: −41.23, −1.39,<jats:italic>p</jats:italic> = .036) and HbA1c (WMD: −0.75, 95% CI: −1.16, −0.34,<jats:italic>p</jats:italic> < .001) levels but results about fasting serum insulin (WMD: 5.51 μU/ml, 95% CI: −2.31, 13.33,<jats:italic>p</jats:italic> = .167) and HOMA‐IR (WMD: −0.07, 95% CI: −0.33, 0.20,<jats:italic>p</jats:italic> = .617) were not meaningful. Sesame may be considered a beneficial agent for human glucose metabolism and can be a part of glucose‐lowering diets.</jats:p>